# Biotech Term Sheet Red Flags Investors Should Never Ignore > Biotech term sheets hide deal-killing provisions that even experienced investors miss. This guide breaks down the specific red flags to catch before you sign, the primary sources to verify them, and the checklist to run on every deal. ## What Are the Most Dangerous Red Flags in a Biotech Term Sheet? The most dangerous red flags in a biotech term sheet fall into four categories: liquidation preference stacking that wipes out common holders, IP ownership gaps that let founders or institutions claw back core assets, milestone definitions vague enough to never trigger, and governance clauses that strip investor control precisely when the company is most at risk. Missing any one of these can turn a promising oncology or rare-disease bet into a total loss regardless of how good the science looks. ## Why Do Liquidation Preference Terms Deserve the Most Scrutiny? Liquidation preferences determine who gets paid first and how much when a company is acquired or wound down. The red flags to watch are participating preferred with uncapped participation (sometimes called double-dip preferred), preference multiples above 1.5x in early rounds, and stacked preferences across multiple series where each new round sits senior to the last. In a biotech where an acquirer pays a modest premium to pipeline value, a stack of participating preferred can leave Series A and later-round investors with nearly nothing after senior holders collect their multiples. Verify the full cap table waterfall, not just the current round terms, and model at least three exit-price scenarios before accepting any participation feature. ## How Can IP Ownership Issues Destroy a Biotech Investment? Biotech value is almost entirely IP value, so ownership gaps are existential. The specific red flags include: core patents licensed exclusively from a university or government lab with reversion rights triggered by commercialization milestones or funding gaps; inventor assignment agreements that were signed after filing rather than before; co-inventor disputes that have not been adjudicated; and compound or platform technology that straddles multiple license agreements from different institutions. Verify ownership at the USPTO Patent Full-Text and Image Database (patents.google.com mirrors it and adds citation data). Cross-check the assignment chain on each priority application. Pull the actual license agreement from SEC EDGAR if the company is public or has filed an S-1; Material Agreements sections list license terms. For academic spinouts, request the university tech-transfer agreement directly and look for the sublicensing consent clause, the diligence obligations, and the termination triggers. ## What Clinical and Regulatory Red Flags Appear Before a Term Sheet Is Signed? The company's regulatory and clinical history is a matter of public record. Red flags hiding in plain sight include: a clinical hold that was lifted but never fully explained in public disclosures; a Complete Response Letter from the FDA whose specific deficiencies the company has not addressed in writing; trial designs that changed primary endpoints after unblinding (detectable on ClinicalTrials.gov by comparing protocol versions); and no pre-IND or Type B meeting minutes cited in the data room. Search ClinicalTrials.gov by NCT number and click the History of Changes tab to see every protocol amendment and the date it was made. Search the FDA's 483 database and Warning Letter database for the company's manufacturing partners. Cross-reference published results against the registered primary endpoint on PubMed using the NCT number as a search term. ## Which Governance and Control Clauses Put Investors at the Most Risk? Governance red flags are often buried in schedules and defined terms. Watch for: protective provisions that require supermajority approval of all existing preferred holders (not just the lead series) to issue new equity, meaning a single prior investor can block a dilutive but necessary financing; broad drag-along rights controlled by founders or a single major shareholder rather than by investor majority; anti-dilution provisions that convert to full ratchet rather than broad-based weighted average; and information rights that expire at an IPO, leaving later-stage investors blind after the company is public. Also flag any clause that ties a board seat to a minimum ownership threshold without a cure period, because regulatory delays common in biotech can force bridge rounds that accidentally trip that threshold and remove your board representation at the worst possible moment. ## What Milestone and Valuation Mechanics Are Commonly Abused? Convertible notes and SAFEs with uncapped or very high-cap valuations detached from any clinical de-risking event are common in early biotech rounds and regularly produce painful dilution at Series A. More subtle abuses include: milestone-based tranches where the milestone is defined as initiation of a Phase 2 study rather than a specific efficacy signal, allowing management to satisfy the trigger with a poorly designed trial; and earnout provisions in acquisitions that depend on FDA approval timelines entirely outside any party's control without a termination backstop. Insist that every milestone be tied to an objective, independently verifiable event, preferably one that is also reported publicly (such as a ClinicalTrials.gov status update or an FDA action date on a PDUFA calendar). ## Short Checklist: Run This Before You Sign Any Biotech Term Sheet - Liquidation waterfall modeled at 0.5x, 1x, 2x, and 5x entry valuation for all share classes - Every core patent assigned (not just licensed) to the company; assignment chain verified on USPTO - License reversion triggers and diligence obligations pulled from the full license text on EDGAR or directly from tech-transfer office - ClinicalTrials.gov History of Changes reviewed for endpoint amendments post-unblinding - FDA Warning Letters and 483s checked for all named CMOs and CROs - Anti-dilution mechanics confirmed as broad-based weighted average - Drag-along controlled by investor majority, not founder majority - Board seat tied to ownership threshold with at least a 90-day cure period - All milestone tranches tied to objectively verifiable, publicly reported events - Information rights survive IPO for at least 12 months ## How Can You Automate This Verification Process? Running every one of these checks manually across FDA databases, EDGAR, ClinicalTrials.gov, USPTO, and PubMed takes dozens of hours per deal. MedFuel Intel builds AI-powered due-diligence reports that pull primary-source data from all five databases, flag red-flag clauses against a continuously updated checklist, and deliver a verified summary before you spend time in a data room. Run a free Red Flag Screener on your next deal at https://medfuelintel.com and see which issues surface in minutes rather than days. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/biotech-term-sheet-red-flags-investors-should-never-ignore). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.